Maropitant: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Maropitant.svg|Maropitant | |||
File:Injectable Cerenia.jpg|Injectable Cerenia | |||
File:Oral Cerenia.jpg|Oral Cerenia | |||
</gallery> | |||
Latest revision as of 01:11, 20 February 2025
Maropitant is a neurokinin-1 (NK1) receptor antagonist that is used in veterinary medicine to prevent vomiting and nausea in dogs and cats. It is marketed under the trade name Cerenia by Zoetis and is available in both injectable and oral forms.
Etymology[edit]
The name "Maropitant" is derived from the chemical name of the drug, which is (2S,3S)-2-benzhydryl-N-[(5-tert-butyl-2-pyridyl)methyl]piperazine-1-carboxamide.
Pharmacology[edit]
Maropitant is a potent, selective, non-peptide antagonist of the neurokinin 1 (NK1) receptor. The NK1 receptor is a G-protein coupled receptor located in the central and peripheral nervous system. It is primarily involved in the transmission of pain, and its activation leads to the sensation of nausea and the reflex of vomiting. By blocking the NK1 receptor, maropitant prevents the action of its natural ligand, substance P, thus preventing the sensation of nausea and the reflex of vomiting.
Uses[edit]
Maropitant is used in dogs and cats to prevent and treat acute vomiting, and to prevent vomiting due to motion sickness. It is also used to prevent vomiting associated with chemotherapy in dogs.
Side effects[edit]
The most common side effects of maropitant include hypersalivation, diarrhea, anorexia, and lethargy. In rare cases, it can cause changes in behavior, such as hyperactivity or aggression.


